Halozyme Therapeutics | HALO - SCHULD





SCHULD Veränderung Datum
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amarin USD 0 0 2025-03
Amgen USD 54.6B 17M 2025-12
Baxter International USD 9.78B 68M 2025-12
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 1.28B 87.39M 2025-12
DBV Technologies USD 8.59M 295K 2025-09
Eli Lilly USD 42.5B 3.6M 2025-12
Esperion Therapeutics USD 262.92M 1.76M 2024-09
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Intrexon USD 0 13.82M 2024-06
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
MannKind USD 119.91M 73.09M 2025-09
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 0 0 2022-06
Pfizer USD 63.96B 3.11B 2025-12
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
United Therapeutics USD 200M 100M 2025-03
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12